Owing to its dNTPase activity, SAMHD1 can degrade the analog cytarabine triphosphate and reduce its concentrations in cells, such as the patient-derived acute myeloid leukemia blasts, thereby posing a significant barrier to the effective analog cytarabine-based treatment (45). This evidence concerns the gene SAMHD1 and acute myeloid leukemia.